Investing.com -- Sandoz (SIX:SDZ) shares slid around 3% Wednesday after the Swiss drugmaker reported first-quarter 2025 sales that came in 5% below company-compiled consensus. Excluding the impact ...

As the global leader in generic and biosimilar medicines, Sandoz is committed to its purpose of "pioneering access for patients" and has benefited over 900 million patients worldwide with ...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...

Under the terms of the agreement, Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the US. The core sequence patent for ipilimumab ...

Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to develop and ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz (SIX:SDZ) said a proposal by the CEOs of Novartis (SIX:NOVN) and Sanofi (NASDAQ:SNY) to introduce a Europe-wide list price for new ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and ...

The increasing prevalence of antibiotic resistance in pathogenic bacteria poses a great healthcare problem worldwide. Azithromycin (AZM) is a very effective macrolide antibiotic to treat many ...

Sandoz backs Avecho in $3m CBD sleep capsule play Neurotech also eyes sleep as secondary endpoint in CBD trials The hot sleep space is led by companies like Resmed and Compumedics Melbourne-based ...